FTC and 13 States Sue to Block Covetrus's $3.5 Billion Purchase of MWI

Veterinary medicine in the United States runs through a small number of national distributors. Clinics that need vaccines, antibiotics, gloves, gauze and surgical instruments rarely buy those items one box at a time from manufacturers. They contract with distributors that carry thousands of products and extend discounts and rebates smaller suppliers cannot match. Two of the largest names in that chain are Covetrus Inc., based in Portland, Maine, and MWI Veterinary Supply Inc., a unit of Cencora Inc. Covetrus has been owned by Clayton, Dubilier & Rice LLC and TPG Inc. since a 2022 take private transaction.

The sale was announced in February 2026. Cencora would receive $1.25 billion in cash and $800 million in preferred equity, and would keep a 34.3 percent non-controlling common equity stake in the combined company. The headline value placed on MWI was $3.5 billion. Cencora's fiscal 2026 guidance did not assume a close before its fiscal year ended on September 30, 2026. The transaction still had to clear antitrust review, which became the central obstacle.

On November 13, 2026, the Federal Trade Commission voted 2-0 to authorize staff to seek a permanent injunction, then filed a complaint in the US District Court for the Southern District of New York. Attorneys general from 13 states joined the case: Arizona, Arkansas, California, Colorado, Maine, Michigan, Minnesota, Nebraska, New York, North Carolina, Ohio, Oregon and Texas. The matter is file number 2610070, and the defendants include CVET Topco, Clayton, Dubilier & Rice, TPG, Covetrus, Cencora and MWI. The states seek a preliminary injunction and ultimately a ruling that the merger is illegal, while the companies have agreed to a temporary restraining order that prevents them from closing before December 4, 2026.

The FTC alleges that the transaction merges the two largest suppliers in veterinary clinic distribution and in distribution to large corporate accounts, that the combined firm would drive up costs for veterinary clinics, decrease service quality and increase prices for pet owners, and that the combination would leave both markets highly concentrated and presumptively unlawful under current antitrust case law and the FTC and DOJ joint merger guidelines. Both companies supply pharmaceuticals, vaccines, white goods such as gloves, gauze and syringes, surgical supplies and thousands of other products, plus related services, to customers ranging from single veterinarian practices to corporate accounts with hundreds of clinic locations.

Key Facts

Reuters reported on November 13, 2026 that the US antitrust regulator filed a lawsuit that Friday in a New York federal court to block Cencora's $3.5 billion sale of its MWI Animal Health unit to Covetrus, arguing the deal would raise costs for clinics and pet owners. Reuters also reported that Cencora shares were up about 2 percent in midday trading, and that J.P. Morgan analysts said they do not expect the challenge to hurt Cencora's forecast, although the brokerage said the company would likely look for alternative MWI transactions if the sale is ultimately blocked.

The Federal Trade Commission reported on November 13, 2026 that Daniel Guarnera, director of its Bureau of Competition, had framed the case around rivalry that already exists. "Veterinarians and millions of American pet owners benefit when veterinary distributors compete by offering lower prices and better service," he said. "This transaction will reduce competition in an already concentrated market and drive up prices for veterinarians and their customers." The complaint says Covetrus responded to MWI's aggressive pricing by cutting its own prices and offering rebates through its VetSuite program, and that Vetcove, an online platform where veterinarians compare prices and leverage one distributor's pricing against the other, intensified that rivalry into what the agency calls an all out price war.

The New York attorney general's office reported on November 13, 2026 that Letitia James had joined a bipartisan coalition of 12 other states and the FTC in the suit. Her office said the acquisition would give Covetrus power to set higher prices, provide lower quality services and control more than half of the veterinary clinic distribution market nationwide. James said that a trip to the vet should never break the bank, that pet owners are already paying enormous prices for care, and that the merger would threaten to drive costs even higher.

The Underbite reported on November 13, 2026 that Covetrus's distribution network spans 28 distribution centers, according to an October release from software vendor RELEX. Covetrus says the suit rests on a narrow and outdated view of the market: manufacturers sell directly, distributors compete nationally and regionally, and online marketplaces used by more than 60 percent of US practices let clinics compare prices and order from 40 or more distributors and thousands of manufacturers. North Carolina Attorney General Jeff Jackson said the merger would raise prices for pet owners and that his state was going to court to stop it, citing American Veterinary Medical Association figures showing dog owners spent an average of nearly $600 on veterinary care in 2025 and cat owners about $530.

Analysis

The structural argument in the complaint is that this is not a case about a dominant buyer squeezing suppliers but about a horizontal merger between the two firms that set the reference price for everyone else. The FTC says national distribution networks let Covetrus and MWI deliver quickly and offer discounts and rebates smaller rivals cannot match, and that specialty distributors, manufacturers, retailers and other fringe suppliers do not impose a meaningful competitive constraint. New entrants, the agency adds, face structural barriers. If that account holds, the deal does not merely shift market share. It removes the benchmark against which clinics and corporate groups negotiate.

What this really means is that the fight will turn on market definition rather than on the arithmetic of concentration. Covetrus's defense is essentially that the relevant market is broader than the FTC says, pointing to direct purchasing from manufacturers, to national and regional distributors and to online marketplaces used by more than 60 percent of US practices. The agency's answer is that those channels are peripheral. The complaint does not concede the rise of comparison shopping. It argues that Vetcove intensified head to head rivalry between Covetrus and MWI rather than disciplining it, because the platform let veterinarians leverage one distributor's pricing against the other.

The buyer side matters just as much. New York's release says corporate practice groups can buy 65 to 90 percent of supplies from a single distributor, and that this volume is what earns the discounts passed on to pet owners. A distributor with more than 50 percent of the relevant markets would, on the coalition's theory, have unmatched power to demand higher prices from those groups. The states are not arguing that clinics will lose access to products. They are arguing that the terms of access will worsen, and that the damage will arrive quietly as smaller rebates and thinner service rather than as an obvious shortage.

Why It Matters

Pet care is one of the few household categories where consumers rarely see a price before they are already committed. The AVMA figures cited by North Carolina put average annual veterinary spending at nearly $600 for dog owners and about $530 for cat owners in 2025, and those numbers sit downstream of the distribution layer this case targets. If the coalition is right that the merger would raise distributor prices, the effect would reach households through clinic invoices rather than through a single visible price increase.

The case also tests how enforcers treat mid sized, unglamorous supply chains. Veterinary distribution is a logistics and credit business built on 28 distribution centers, thousands of product lines and rebate programs such as VetSuite, which Covetrus says has 4,000 member practices and has delivered $150 million in cumulative member benefits at an average of $30,000 per practice per year. Those numbers are the company's own evidence that scale produces savings. The FTC's theory is that the same scale, concentrated in one firm, produces the power to stop passing those savings along. The breadth of the coalition, with 13 states joining a 2-0 Commission vote, suggests the case is neither a partisan split inside the agency nor one state's local concern. The naming of Clayton, Dubilier & Rice and TPG alongside Covetrus keeps private equity ownership in the factual frame.

Next Up

The immediate milestone is December 4, 2026, the date before which the companies have agreed not to complete the transaction under the temporary restraining order. Before then, the Southern District of New York will weigh the states' request for a preliminary injunction while the FTC presses for a permanent injunction. Cencora's quarterly filing says the agency's request for additional information and documentary materials arrived on May 20, 2026, nearly six months before the suit.

What follows depends on how the court draws the market. If the FTC's definition holds, a share of more than 50 percent of veterinary clinic distribution becomes presumptively unlawful, and the parties would need a strong efficiency defense built on claims such as the VetSuite savings. If Covetrus persuades the court that direct manufacturer sales and online marketplaces belong inside the market, the concentration figures fall and the case weakens.